KDM6B and rheumatoid arthritis: The hydrogen sulfide (H2S) donor S-propargyl cysteine (SPRC/ZYZ-802) developed by our team alleviates the inflammatory response and inhibits HDAC6 and JMJD3 in RA models [108,116]; it might be a potential agent for RA treatment in the future.